Claims for Patent: 6,551,620

Summary for Patent: 6,551,620

Title:	Pellet formulation for the treatment of the intestinal tract
Abstract:	An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Inventor(s):	Otterbeck; Norbert (Uberlingen, DE)
Assignee:	Dr. Falk Pharma GmbH (Freiburg, DE)
Application Number:	09/906,494
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,551,620
Patent Claims:	1. An orally administrable pharmaceutical pellet formulation having a controlled release profile for the treatment of the intestinal tract, which comprises a core and an enteric coating and optionally pharmaceutically tolerable additives, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically acceptable salt, wherein the active compound is present in the core in a non gel-forming polymer matrix which is essentially insoluble in the intestinal tract and permeable to intestinal fluids and the active compound, the matrix-forming polymer making up at least 1% by weight of the total weight of the core, and wherein the matrix-forming polymer is selected from the group consisting of poly(ethyl acrylate, methyl methacrylate) and poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride). 2. The pellet formulation as claimed in claim 1, wherein the matrix-forming polymer makes up 4-10% by weight of the total weight of the core. 3. The pellet formulation as claimed in claim 1 wherein the polymer matrix extends through the entire core and the active compound is homogeneously dispersed in the polymer matrix. 4. The pellet formulation as claimed in claim 1, wherein the active compound is 5-aminosalicylic acid. 5. The pellet formulation as claimed in claim 1, wherein the enteric coating comprises a methacrylic acid copolymer or methylhydroxypropyl-cellulose phthalate. 6. The pellet formulation as claimed in claim 5, wherein the enteric coating contains poly(methacrylic acid, methyl methacrylate), the polymer containing free carboxyl groups as functional groups. 7. The pellet formulation as claimed in claim 1, wherein the pellet only comprises one coating layer. 8. The pellet formulation as claimed in claim 1, comprising, as an active compound, 5-aminosalicylic acid in a poly(ethyl acrylate, methyl methacrylate) 2:1 matrix, the polymer containing ester groups as functional groups, in the core and an enteric coating which comprises poly(methacrylic acid, methyl methacrylates) 1:1 or 1:2, the polymer containing free carboxyl groups as functional groups, and optionally pharmaceutically tolerable additives. 9. The pellet formulation as claimed in claim 1, wherein the release of active compound in 0.1 M HCl after 2 hours is less than 10%, and in artificial gastric juice at pH of about 6.8 after 30 minutes is 10-30%, after 2 hours is 40-60%, and after 6 hours is at least 80%. 10. A pharmaceutical formulation, which comprises pellets as claimed in claim 1. 11. The pharmaceutical formulation as claimed in claim 10, which is a gelatin capsule or a tablet which contains the pellets. 12. A method for treating, or preventing the recurrence of intestinal disorders, secondary disorders resulting therefrom, or intestinal cancer comprising administering the pellet formulation of claim 1 to a patient in need thereof. 13. The method of claim 12, wherein the intestinal disorder is an inflammatory intestinal disorder in the active or remission phase. 14. The method of claim 12, wherein the intestinal disorder is a polyp in the gastrointestinal tract. 15. The method of claim 14, wherein the polyp is an adenoma or shows polypous growth. 16. The method of claim 14, wherein the pellet formulation lowers the recurrence rate of adenomas or colorectal polyps compared to a method free of administering the formulation. 17. A method for treating colon cancer comprising administering the pellet formulation of claim 1 to a patient in need thereof.